[en] Objective: To discuss the safety and curative effect of CT-guided percutaneous argon-helium cryoablation in treating leiomyosarcoma. Methods: A total of 25 patients with leiomyosarcoma, who were treated at authors' hospital during the period from January 2012 to January 2016, were included in this study. CT-guided percutaneous argon-helium cryoablation was performed in all patients. The local changes of target lesions, the progression-free survival (PFS) and the survival rate were dynamically checked, and the complications were recorded. Results: CT examination performed immediately after argon-helium cryoablation indicated that radical frozen ablation was achieved in 13 patients (52%), significant tumor-reductive frozen ablation in 11 patients (44%), effective tumor-reductive frozen ablation in one patient (4%), and invalid tumor-reductive frozen ablation in 0 patient. Follow-up CT examination performed at 3 months after argon-helium cryoablation showed that, based on solid tumor evaluation criteria, complete remission (CR) was obtained in 14 patients, partial remission (PR) in 8 patients and stable disease (SD) in one patient, the total remission rate (CR + PR) was 88%. The local PFS time was (9.4 ± 6.2) months. The one-, 2- and 3- year survival rates were 64%, 48% and 32% respectively. In this group of cases, neither serious complications such as haemorrhage or tumor lysis syndrome nor procedure-related death occurred. Postoperative mild and moderate complications included fever, skin frostbite, immediate postoperative local pain exacerbation, nerve damage, etc., all of which disappeared or became relived after symptomatic treatment. Conclusion: For the treatment of leiomyosarcoma, CT-guided percutaneous targeted argon-helium cryoablation has certain and definite short-term curative effect. CT-guided argon-helium cryoablation is a safe, reliable and minimally-invasive treatment, this technique is worth popularizing in clinical practice. (authors)